Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.81 |
| ▸ | MMP9 | P14780 | 15/20 | 0.81 |
| ▸ | MMP8 | P22894 | 12/20 | 0.81 |
| ▸ | MMP13 | P45452 | 12/20 | 0.81 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.65 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640744 | 1.00 | MMP2 (0.81) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL12273360 | 0.92 | MMP9 (0.69) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL11956659 | 0.92 | MMP2 (0.81) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL22309184 | 0.92 | MMP2 (0.81) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL29521288 | 0.92 | MMP2 (0.81) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| Hydrochloric Acid SCHEMBL22289716 | 0.91 | MMP2 (0.80) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL11956653 | 0.91 | MMP2 (0.80) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL5458647 | 0.90 | MMP9 (0.79) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL13253256 | 0.89 | MMP9 (0.80) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL3468444 | 0.89 | MMP9 (0.80) | MMP2MMP9MMP8MMP13ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210928-A1 | SCREENING METHOD FOR LAMININ 511 PRODUCTION PROMOTING AGENT, BASAL EPIDERMAL LAYER STABILIZING AGENT, AND/OR EPIDERMAL STEM CELLS REDUCTION INHIBITING OR PROLIFERATION PROMOTING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | MMP1, MMP17, MMP25 | MMP2 16/4885MMP9 4/4885MMP8 18/4885 |
| US-20230210928-A1 | SCREENING METHOD FOR LAMININ 511 PRODUCTION PROMOTING AGENT, BASAL EPIDERMAL LAYER STABILIZING AGENT, AND/OR EPIDERMAL STEM CELLS REDUCTION INHIBITING OR PROLIFERATION PROMOTING AGENT | KRT18, RPL37A, MKI67 | MMP2 548/4885MMP9 168/4885MMP8 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.